Quick gene test may personalize stroke care

NCT ID NCT06943586

Recruiting now Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a fast genetic test can help doctors pick the best blood-thinning medication for people who have had a minor stroke or a high-risk mini-stroke (TIA). The test checks a gene called CYP2C19, which affects how the body processes certain antiplatelet drugs. Researchers will see if they can get test results within 6 hours during a hospital stay. About 200 adults will take part, and they will be followed for 90 days to check for new strokes or recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CYP2C19 genotype guided dual antiplatelet therapy (DAPT)
What this could lead to: If successful, this could show that bedside genetic testing is feasible and may help doctors choose the right antiplatelet drug for each stroke patient, potentially reducing future strokes.
What could go wrong: This is a small feasibility study, not designed to prove that genetic testing improves outcomes. The 6-hour turnaround for results is challenging, and the approach may not work in all hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MINOR ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE TRANSIENT ISCHEMIC ATTACK (TIA)

Contacts and locations

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.